EUCTR2009-011889-28-DEActive, not recruitingPhase 1
Phase III study of chemotherapy in combination with ATRA with or without gemtuzumab ozogamicin in patients with acute myeloid leukemia and NPM1 gene mutation - AMLSG 09-09
niversity of Ulm0 sites588 target enrollmentStarted: May 27, 2009Last updated:
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 588
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Both female and male patients meeting the mentioned inclusion and exclusion criteria will be included in this clinical trial, because the risk to get AML does not depend on a patient’s gender. Patients must meet all of the following inclusion criteria to be eligible for enrollment into the study
- •Patients with confirmed diagnosis of acute myeloid leukemia according to the World Health Organization (WHO) classification
- •Presence of NPM1 mutation as assessed in one of the central AMLSG reference laboratories.
- •Age = 18 years. There is no upper age limit.
- •No prior chemotherapy for leukemia except hydroxyurea to control hyperleukocytosis if needed for up to 5 days during the diagnostic screening phase.
- •Non-pregnant and non-nursing. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within a sensitivity of at least 25 mIU/mL within 72 hours prior to registration.
- •Female patients in the reproductive age and male patients must agree to avoid getting pregnant or to father a child while on therapy and within one year after the last dose of chemotherapy. Women of child-bearing potential must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control - one highly effective method (e.g., IUD, hormonal, tubal ligation, or partner’s vasectomy), and one additional effective method (e.g., latex condom, diaphragm, or cervical cap). ). Women of childbearing potential” is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months.
- •Men must use a latex condom during any sexual contact with women of childbearing potential, even if they have undergone a successful vasectomy.
- •Signed written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 441
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 147
Exclusion Criteria
- •The presence of any of the following will exclude a patient from study enrollment:
- •AML with other recurrent genetic changes (according to WHO 2008):
- •AML with t(8;21)(q22;q22); RUNX1-RUNX1T1
- •AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
- •AML with t(15;17)(q22;q12); PML-RARA (or other translocations involving RARA)
- •AML with t(9;11)(p22;q23); MLLT3-MLL (or other translocations involving MLL)
- •AML with t(6;9)(p23;q34); DEK-NUP214
- •AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1
- •Performance status WHO >2
- •Patients with ejection fraction < 50% by MUGA or ECHO scan within 14 days of day 1
- •Organ insufficiency (creatinine >1.5x upper normal serum level; bilirubin, AST or ALP >2.5x upper normal serum level, not attributable to AML; heart failure NYHA III/IV; severe obstructive or restrictive ventilation disorder)
- •Uncontrolled infection
- •Severe neurological or psychiatric disorder interfering with ability of giving an informed consent
- •Patients with a currently active” second malignancy other than non-melanoma skin cancers. Patients are not considered to have a currently active” malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse within one year.
- •Known positive for HIV,active HBV, HCV, or Hepatitis A infection
- •Bleeding disorder independent of leukemia
- •Patients with a currently active” second malignancy other than non-melanoma skin cancers. Patients are not considered to have a currently active” malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse within one year.
- •No consent for registration, storage and processing of the individual disease-characteristics and course as well as information of the family physician about study participation.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Phase III study of chemotherapy in combination with ATRA with or without gemtuzumab ozogamicin in patients with acute myeloid leukemia and NPM1 gene mutatioadult patients with AML and NPM1 mutationEUCTR2009-011889-28-ATniversity of Ulm588
Completed
Phase 1
Phase I/II study of combination chemotherapy with Paclitaxel and TS-1 and Cisplatin for unresectable/ recurrent gastric cancerunresectable or recurrent gastric cancerJPRN-UMIN000004729School of Medicine, Keio University40
Completed
Phase 2
A Phase II study of combination chemotherapy with TS-1 and Trastuzumab for patients with HER2 positive advanced or recurrent gastric cancer.advanced or recurrent gastric cancerJPRN-UMIN000008220Osaka medical center for cancer and cardiovascular diseases20
Completed
Phase 1
Phase I-II study of combination chemotherapy with Irinotecan and Gemcitabine for clear cell or mucinous ovarian cancerClear cell or mucinous ovarian cancerJPRN-UMIN000005952Osaka university, faculty of medicine40
Completed
Phase 2
A phase II study of combination chemotherapy with carboplatin plus S-1 in advanced lung squamous cell carcinomaung cancerJPRN-UMIN000006983Hamamatsu University School of Medicine50